The UK and US have finalized a landmark commercial pact that will ensure zero levies on UK medicine products entering the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to boost expenditure on medicines through the National Health Service (NHS). This pledge secures that tariffs on these key products will be held at zero for a timeframe of the next three years.
This agreement is in response to recent statements to hike duties on patented pharmaceutical imports, with potential rates discussed reaching one hundred percent.
"This deal with the United Kingdom bolsters the international landscape for cutting-edge drugs and introduces long-overdue equity to U.S.–U.K. medicine commerce," an announcement noted.
Commercial Importance
Pharmaceuticals represent one of the the United Kingdom's largest export categories to the United States, which is easily the largest market for large companies like GSK and AstraZeneca.
Statistics show that in the year prior to September, the UK exported medicines totaling £11.1bn to the US. This value made up 17.4% of British export trade in that span.
"This guarantee secures jobs, stimulates capital expenditure and facilitates the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary stated.
Specific UK Commitments
The agreement entails several specific changes from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to raise total NHS spending on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Payback Limit: The sum drug companies must refund to the NHS to control costs will be limited at 15%. Previously, rebates were more than twenty percent.
Broader Context
The deal comes amid a ongoing dispute between the sector and the UK government over medicine costs and approval rates.
This friction were heightened by arguments that US customers were paying significantly more for the same drugs than people in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar investments have been directed toward American operations.
One official publicly accepted that the NHS had to spend more on medicines, noting that its spending on drugs had decreased as a proportion of its overall budget over the past decade.
